Novartis NVS
-
DEALTALK- Novartis' Vasella exit opens door to Roche stake sale
* Novartis ' one-third stake in Roche built up under Vasella
-
Novartis says has no intention of buying Actavis
ZURICH, May 16 (Reuters) - Novartis has no plans to bid for U.S.-based generic drugmaker Actavis, which is the subject of intense takeover speculation, a spokesman for the Swiss drugmaker said on Thursday.
-
Actavis (ACT), which has rebuffed overtures from both Valeant (VRX) and more recently Mylan (MYL), may soon receive a bid from Novartis ( NVS ), WSJ says. "Intense price competition and fewer ...
… which has rebuffed overtures from both Valeant ( VRX ) and more recently Mylan ( MYL ), may soon receive a bid from Novartis ( NVS ), WSJ says. "Intense price competition and fewer opportunities to cash in on patent expirations," are fueling …
-
Shares of Insmed ([[INSM]] +3.6%) pop after the company says the European Patent Office will grant a patent on ARIKACE, the company's clinical stage, inhaled treatment for cystic fibrosis patients ...
… infections. In an exhaustive rundown, SA contributor Scott Matusow claims the drug is a superior alternative to Novartis ' ( NVS ) TOBI for a number of reasons and also says INSM could capture a significant portion of the $424M (annually) market …
-
New Morningstar Analyst Report - Amgen
… entered the market in Europe, led by Novartis ' Sandoz division. These biosimilars ..... with established drugs such as Novartis ' Reclast and cheaper generic bisphosphonates ..... so far indicates superiority to Novartis ' NVS blockbuster Zometa. We believe …
-
New Morningstar Analyst Report for Biogen Idec Inc
… novel oral therapies, such as Novartis ' Gilenya and Sanofi's Aubagio ..... Tecfidera's growth trajectory given Novartis ' first-mover advantage in the ..... established injectable drugs and Novartis ' NVS oral multiple sclerosis drug Gilenya …
-
New Morningstar Analyst Report for Baxter International Inc.
… of Medical Products, spent 14 years at Lilly; and Ludwig Hantson, head of BioScience, spent more than 20 years at Novartis and Johnson & Johnson. Overall, we think Baxter's capital allocation strategy (split relatively evenly between capital …
-
New Morningstar Analyst Report for Roche Holding AG
… pooled voting rights--including board members Andre Hoffmann and Andreas Oeri--owns 45% of voting shares, and Novartis owns 33% of voting shares. Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical …
-
Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
… candidates for the treatment of cancers and other diseases. The first article looked at Array's collaboration with Novartis ( NVS ) , Amgen ( AMGN ) , AstraZeneca ( AZN ) and other companies that are developing some promising therapies. This article …
-
Novartis , BT push European shares to fresh 5-yr peak
LONDON, May 10 (Reuters) - European shares scaled fresh five-year highs on Friday, led by healthcare group Novartis and telecoms firm BT on positive corporate news, and traders said key indexes had...